Elite Pharmaceuticals Inc /NV/ reported fiscal 2026 results with revenue of $148.9M, up 77% from $84M a year earlier, and net income attributable to common shareholders of $44.9M compared with a net loss of $4.3M in FY 2025.
Financial Highlights
- Revenue: $148.9M for FY 2026, up from $84.0M in FY 2025 (77% YoY).
- Net income: $44.9M attributable to common shareholders for FY 2026, versus a net loss of $4.3M in FY 2025.
- Diluted earnings per share: Not reported in the provided MD&A; omitted.
Business Highlights
- Revenue growth was driven by new product launches and increased sales of Elite-labelled products after shifting away from licensing arrangements.
- The company scaled up manufacturing volumes and saw a significant rise in accounts receivable to support higher production and commercial activity.
- Multiple product launches expanded the portfolio, including Oxy APAP, Naltrexone, Phentermine, Lisdex capsules and methadone tablets.
- R&D spending declined as resources were reallocated to commercial operations and supporting product rollouts.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.